Clinical trials: Response Rates
- Condition Response Rates
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Breast Neoplasms
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Trial name
- NCT00174343
- Testing
- exemestane (Aromasin®)
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Pfizer
Cancer
Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)
Recently an automated test for measuring cancer cell death in the presence of chemotherapy has been developed. This test has been called the MiCK assay during the ten year development phase and is now called Correct Chemo.
- Trial name
- NCT02137811
- Testing
- MICK Assay
- Where
- 2 sites in United States, Canada
- Sponsor
- Pierian Biosciences